Capecitabine

Generic Name: Capecitabine

Brand Names: Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₂₂FN_₃O_₆

CAS Number: 154361-50-9

Unique Ingredient Identifier: 6804DJ8Z9U

Background: Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Indication: Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.

Associated Conditions: Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer

Associated Therapies: Chemotherapy

Clinical Trials

A Study of Capecitabine (Xeloda) and Peginterferon Alfa-2a (Pegasys) in Treatment-Naive Participants With Advanced Liver Cancer

Phase 2

Completed

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: Capecitabine
Drug: Peginterferon alfa-2a

First Posted Date: 2015-10-15

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 16

Registration Number: NCT02576964

Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Eribulin
Drug: Sacituzumab govitecan
Drug: Capecitabine
Drug: Gemcitabine
Drug: Vinorelbine

First Posted Date: 2015-10-12

Last Posted Date: 2022-06-15

Lead Sponsor: Gilead Sciences

Target Recruit Count: 529

Registration Number: NCT02574455

Locations: 🇺🇸
Southern Cancer Center, 29653 Anchor Cross Blvd, Daphne, Alabama, United States
🇺🇸
Souther Cancer Center, 3719 Dauphin St., 5 Floor, Mobile, Alabama, United States
🇺🇸
Southern Cancer Center, 3 Mobile Infirmary Circle, Mobile, Alabama, United States

and more 175 locations

A Study of Capecitabine (Xeloda) in Patients With Metastatic Colorectal Cancer

Phase 4

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Capecitabine

First Posted Date: 2015-10-02

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 28

Registration Number: NCT02567331

A Study of Capecitabine (Xeloda) in Participants With Locally Advanced or Metastatic Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: Capecitabine
Drug: Gemcitabine

First Posted Date: 2015-10-01

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 63

Registration Number: NCT02565641

A Study of Capecitabine (Xeloda) in Participants With Advanced or Metastatic Gastric Cancer

Phase 3

Completed

Conditions: Gastric Cancer

Interventions: Drug: Capecitabine
Drug: 5-Fluorouracil
Drug: Cisplatin

First Posted Date: 2015-09-29

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 316

Registration Number: NCT02563054

A Study of Capecitabine (Xeloda) in Combination Chemotherapy Versus Surgery Alone in Participants With Gastric Cancer

Phase 3

Completed

Conditions: Gastric Cancer

Interventions: Drug: Capecitabine
Drug: Oxaliplatin

First Posted Date: 2015-09-25

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1035

Registration Number: NCT02560974

Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer

Phase 2

Active, not recruiting

Conditions: Anal Basaloid Carcinoma
Stage IV Anal Canal Cancer
Recurrent Anal Canal Carcinoma
Anal Squamous Cell Carcinoma
Metastatic Anal Canal Carcinoma
Stage IIIB Anal Canal Cancer
Anal Canal Cloacogenic Carcinoma